Sandbox Reserved 1712

Anaplastic Lymphoma Kinase receptor

spinqualitylabelsall models Anaplastic Lymphoma Kinase receptor PDB code: 7n00 Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Background The anaplastic lymphoma kinase (ALK) was first discovered in 1994 as a tyrosine kinase in anaplastic large-cell lymphoma (ALCL) cells. The specific type of tyrosine kinase ALK is classified as is a receptor tyrosine kinase (RTK). Similar to other RTKs, it's an integral protein with extracellular and intracellular domains which are involved in transmembrane signaling and communication within the cell. ALK is commonly expressed in the development of the nervous system. Anaplastic lymphoma kinase receptor (ALKr) is the extracellular portion of the RTK that includes a binding surface for a ligand to bind. When the ALK activating ligand (ALKAL) binds to ALKr, this causes a conformational change of ALKr, allowing two ALKr-ALKAL complexes to interact with each other. This allows the intracellular kinase domain of ALKr to phosphorylate a tyrosine residue on a downstream enzyme, which will activate this enzyme and a signaling cascade. Abnormal forms of ALK are closely related to the formation of several cancers. Structure & Function Domains Figure 1: Anaplastic Lymphoma Kinase and its domains. ALKr is in its inactive state as a monomer and has many different domains (Figure 1) that are important to the formation of the dimerized active state, leading to ALK's main function. The tumor necrosis factor-like domain (TNFL), glycine-rich domain (GlyR), polyglycine extension loop (PXL), and growth factor-like domain (EGF) are the main domains of ALKr and the only domains whose structures have been fully discovered are in color (Figure 1). The EGF (cyan) is the domain that binds to the TMH (transmembrane region), connecting the extracellular portion of ALK to the intracellular kinase domain. TNFL (orange) has a beta-sandwich structure that provides important residues that act as the binding surface for the ligand. GlyR (green) contains 14 rare polyglycine helices that are hydrogen-bound to each other. The hexagonal orientations of these rare helices create a rigid structure which allows it to function as a scaffold to anchor the ligand-binding site on the TNF-like domain while remaining bound to the ligand. The numerous hydrogen bonds create this formation of the helices and the rigidity of the structure. The PXL (pink) connects two of these polyglycine helices, which plays a role in forming important interactions of the dimerized activated state of ALKr. Additional domains are present in ALK monomers (Figure 1), but their structures are not currently known. The heparin binding domains (HBDs), are at the N-terminal end of the monomer. Heparin is a likely activating ligand of ALK. The transmembrane domain (TMH) contains the membrane spanning portion of ALK that transmits extracellular ligand binding into an intracellular signal. The kinase domain is the intracellular portion of ALK that contains the Tyr residues which are auto-phosphorylated when ALK is activated, initiating a signaling cascade. Figure 2: ALK-ALKAL complex, showing the conformation change of ALK from the binding of ALKAL. PDB: 7N00 Membrane Guidance of ALKAL to ALK The first step for the activation of ALKr is to bind the ALK activating ligand (ALKAL) to ALKr. ALKAL is a triple alpha-helix polypeptide structure that signals for a conformational change of ALK. The cell membrane allows for the interaction between the ALKAL and ALKr. The negatively charged phosphate groups on the cell membrane interact with a highly conserved positively charged alpha-helix on ALKAL that faces the membrane. These residues (Lys96, His99, Lys100) guide ALKAL to ALKr and correctly positions ALKAL for its binding surface to face ALKr's ligand site, which allows for a more favorable interaction. This interaction causes a conformational change, forming the ALKr-ALKAL complex (Figure 2). Conformational Change ALKAL binds to ALKr at the TNFL domain, which has important negatively charged residues that form ionic bonds with positively charged residues on ALKAL. These bonds initiate the conformational change, as these residues can only come into close proximity with each other if the conformational change occurs. The PXL and GlyR domains hinge forward when the change is initiated (Figure 2). Glu978, Glu974, Glu859, and Tyr966 are the residues of ALKr that form these bonds with Arg123, Arg133, Arg136, Arg140, and Arg117 of ALKAL. Once the ALKr-ALKAL complex is formed, the dimerization of two ALKr-ALKAL complexes occurs. The main driving force of the interaction between two ALKr-ALKAL complexes that become a dimer are hydrophobic interactions of the PXL loop of one ALKr with the other complex's ALKAL and TNFL domain of ALKr. This dimer of two ALKr-ALKAL complexes is the active form of ALK and is now able to perform its main function of phosphorylation. Role and Function of Dimerized ALKr-ALKAL The value of the ALKr-ALKAL dimer is its rigidity and strength of its structure, being very important for the function of ALK. Each step of building from the ALK monomer to the dimer adds a level of strength in the structure. This makes it more likely to create the conformational change of the intracellular kinase domain. The conformational change of the dimer initiates a conformational change of the intracellular kinase domain of ALK, which causes an autophosphorylation of several tyrosine residues of this domain, ultimately activating the kinase function of ALK. The kinase domain can now phosphorylate another protein or enzyme downstream in the signaling cascade. An example of a kinase that has a similar function to ALK are insulin receptors (IR). Their ligand (insulin) initiates a conformational change, which allows the kinase domain to be autophosphorylated, activating IR and allowing it to activate other enzymes or proteins down multiple possible signaling pathways via phosphorylation. Disease Many residual mutations have been identified that cause constitutive receptor activation. Enhanced receptor interaction or stabilization of active receptors also increase oncogenic potentials (Figure 3). One gain-of-function mutation found in lung adenocarcinoma is His694 and it's mutated to arginine and leads to constitutive activation of ALK (Fig. 3b). The gain-of-function mutation is caused by the increased length of arginine compared to histidine, which allows it to interact with the other ALKr-ALKAL complex via ionic bonding. This creates a stronger interaction between the two complexes, which increases the likelihood for ALK to be activated at any given time, which then also keeps the whole signal pathway activated downstream. Mutation of Gly747 to arginine could cause possible oncogenic potentials which are not specified yet (Fig. 3a), but this mutation would have a similar effect as His694Arg because it is an even bigger increase in length compared to the hydrogen side group of glycine. The change from a nonpolar to polar side group will create ionic bonds with the other ALKr-ALKAL complex, making it an even larger increase of interaction between the two complexes. The F856S and R753Q are two other mutations in ALK that are known to increase cytokine-dependent cell proliferation in certain cells. Figure 3: Mutated residues on ALK that contribute to stabilization of the active state of ALK, leading to many types of cancers. A: Gly747Arg. B: His694Arg. PDB: 7N00

Student Contributors

• Drew Peters
• Hillary Kulavic